Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences

Pharmacogenomics Journal

Volumn 17, Issue 5, 2017, Pages 461-470

  Sivadas, A ^a   Salleh, M Z ^b   Teh, L K ^b   Scaria, V ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19;

ARTICLE; CYP2C19 GENE; DRUG METABOLISM; DRUG TRANSPORT; GENE FREQUENCY; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; HUMAN; MALAY (PEOPLE); NORMAL HUMAN; PHARMACOGENETIC VARIANT; PHARMACOGENOMICS; POPULATION GENETIC STRUCTURE; PRIORITY JOURNAL; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE; WHOLE GENOME SEQUENCING; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC DATABASE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN GENOME; MALAYSIA; MOLECULAR EPIDEMIOLOGY; MOLECULAR GENETICS; PHARMACOGENETICS; POPULATION GENETICS; PROCEDURES;

ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, GENETIC; GENE FREQUENCY; GENETICS, POPULATION; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALAYSIA; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE ANNOTATION; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS;

EID: 84973130319     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.39     Document Type: Article

References (65)

1. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
2. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet 2008; 17: R174-R179.
3. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 2013; 23: 383-394.
4. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010; 632: 99-124.
5. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012; 92: 437-439.
6. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009; 9: 34-41.
7. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745-755.
8. Altman RB, Whirl-Carrillo M, Klein TE. Challenges in the pharmacogenomic annotation of whole genomes. Clin Pharmacol Ther 2013; 94: 211-213.
9. Gamazon ER, Skol AD, Perera MA. The limits of genome-wide methods for pharmacogenomic testing. Pharmacogenet Genomics 2012; 22: 261-272.
10. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 2014; 14: 217-222.
11. Yasuda SU, Zhang L, Huang S-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-423.
12. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006; 7: 1641-1648.
13. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee M-TM et al. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-3834.
14. Giri AK, Khan NM, Grover S, Kaur I, Basu A, Tandon N et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics 2014; 15: 1337-1354.
15. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
16. Abdulla MA, Ahmed I, Assawamakin A, Bhak J, Brahmachari SK, Calacal GC et al. Mapping human genetic diversity in Asia. Science 2009; 326: 1541-1545.
17. Wong L-P, RT-H Ong, Poh W-T, Liu X, Chen P, Li R et al. Deep whole-genome sequencing of 100 Southeast Asian Malays. Am J Hum Genet 2013; 92: 52-66.
18. Wong L-P, JK-H Lai, Saw W-Y, RT-H Ong, Cheng AY, Pillai NE et al. Insights into the genetic structure and diversity of 38 South Asian Indians from deep wholegenome sequencing. PLoS Genet 2014; 10: e1004377.
19. Hatin WI, Nur-Shafawati AR, Zahri M-K, Xu S, Jin L, Tan S-G et al. Population genetic structure of peninsular Malaysia Malay sub-ethnic groups. PLoS One 2011; 6: e18312.
20. Salleh MZ, Teh LK, Lee LS, Ismet RI, Patowary A, Joshi K et al. Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine. PLoS One 2013; 8: e71554.
21. Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics 2014; 15: 1223-1234.
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
24. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31: 3812-3814.
25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
26. Sangkuhl K, Berlin DS, Altman RB, Klein TE. PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev 2008; 40: 539-551.
27. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-D906.
28. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA et al. The variant call format and VCFtools. Bioinformatics 2011; 27: 2156-2158.
29. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
30. Muthiah YD, Lee WL, Teh LK, Ong CE, Ismail R. Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8 2 and CYP2C8 3 are found in Malaysian Indians. J Clin Pharm Ther 2005; 30: 487-490.
31. Teh LK, Zahri MK, Zakaria ZA, Ismail R, Salleh MZ. Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography. J Clin Pharm Ther 2010; 35: 723-728.
32. Seng KC, Gin GG, Sangkar JV, Phipps ME. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia. Asia-Pacific J Mol Biol Biotechnol 2003; 11: 83-91.
33. Zainuddin Z, Teh LK, Suhaimi AWM, Ismail R. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharm Ther 2006; 31: 187-191.
34. Ngow HA, Wan Khairina WM, Teh LK, Lee WL, Harun R, Ismail R et al. CYP2C9 polymorphism: prevalence in healthy and warfarin-Treated Malay and Chinese in Malaysia. Singapore Med J 2009; 50: 490-493.
35. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26: 205-211.
36. Ong CE, Pan Y, Tiong KH, Yiap BC, Tan EL, Pook P et al. Pharmacogenomics in drug therapy and interaction: The role of cytochrome P450. Int e-Journal Sci Med Educ 2008; 2: S6-S10.
37. Teh LK, Hashim H, Zakaria ZA, Salleh MZ. Polymorphisms of UGT1A1 6, UGT1A1 27 & UGT1A1 28 in three major ethnic groups from Malaysia. Indian J Med Res 2012; 136: 249-259.
38. Sutomo R, Talib NA, Yusoff NM, Van Rostenberghe H, Sadewa AH, Sunarti et al. Screening for G71R mutation of the UGT1A1 gene in the Javanese-Indonesian and Malay-Malaysian populations. Pediatr Int 2004; 46: 565-569.
39. Yusoff S, Takeuchi A, Ashi C, Tsukada M, Maamor NH, Zilfalil BA et al. A polymorphic mutation, c.-3279 T4G, in the UGT1A1 promoter is a risk factor for neonatal jaundice in the Malay population. Pediatr Res 2010; 67: 401-406.
40. Pang YS, Yang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z et al. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol 2004; 58: 332-335.
41. Seet WT, Mary Anne TJA, Yen TS. Apolipoprotein E genotyping in the Malay, Chinese and Indian ethnic groups in Malaysia-A study on the distribution of the different apoE alleles and genotypes. Clin Chim Acta 2004; 340: 201-205.
42. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csázár A et al. The apolipoprotein E polymorphism: A comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991; 49: 338-349.
43. Tan CE, Tai ES, Tan CS, Chia KS, Lee J, Chew SK et al. APOE polymorphism and lipid profile in three ethnic groups in the Singapore population. Atherosclerosis 2003; 170: 253-260.
44. Balram C, Sharma A, Sivathasan C, Lee EJD. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56: 78-83.
45. Tee S, Tang P, Loh H. Genetic Association Analysis of Dopamine DRD3 Ser9Gly Polymorphism and Schizophrenia in Malay Population. Iran J Public Health 2011; 40: 6-10.
46. Rehman A, Rasool AHG, Naing L, Roshan TM, Rahman ARA. Influence of the Angiotensin II type I receptor gene 1166 A4C polymorphism on BP and aortic pulse wave velocity among Malays. Ann Hum Genet 2007; 71: 86-95.
47. Tai ES, Sim XL, Ong TH, Wong TY, Saw SM, Aung T et al. Polymorphisms at newly identified lipid-Associated loci are associated with blood lipids and cardiovascular disease in an Asian Malay population. J Lipid Res 2009; 50: 514-520.
48. Yeoh AE-J Luy, JY-S Chan, Chan YH, Ariffin H, Kham SK-Y, Quah TC et al. Genetic susceptibility to childhood acute lymphoblastic leukemia shows protection in Malay boys: results from the Malaysia-Singapore ALL Study Group. Leuk Res 2010; 34: 276-283.
49. Choo SC, Loh SP, Khor GL, Sabariah MN, Rozita R. MTHFR C677T polymorphism, homocysteine and B-vitamins status in a sample of Chinese and Malay subjects in Universiti Putra Malaysia. Malays J Nutr 2011; 17: 249-258.
50. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2012.
51. Adler D, Murdoch D. rgl: 3D visualization device system (OpenGL). R Packag. version 0.92 2012.
52. Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol 2006; 4: e72.
53. Weir B, Cockerham C. Estimating F-statistics for the analysis of population structure. Evolution (N Y) 1984; 38: 1358-1370.
54. Cadzow M, Boocock J, Nguyen HT, Wilcox P, Merriman TR, Black MA. A bioinformatics workflow for detecting signatures of selection in genomic data. Front Genet 2014; 5: 293.
55. Urban TJ. Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 2013; 14: 345-348.
56. Drögemöller BI, Wright GE, Niehaus DJ, Emsley RA, Warnich L. Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 2011; 12: 1717-1728.
57. Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacogenomics summary. Pharmacogenet Genomics 2010; 20: 642-644.
58. Lee S-C, Ng S-S, Oldenburg J, Chong P-Y, Rost S, Guo J-Y et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006; 79: 197-205.
59. Kawaguchi DM, Glatt SJ. GRIK4 polymorphism and its association with antidepressant response in depressed patients: A meta-Analysis. Pharmacogenomics 2014; 15: 1451-1459.
60. Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet 2008; 83: 337-346.
61. Wang Z, Wang J, Tantoso E, Wang B, Tai AYP, Ooi LLPJ et al. Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci. Hum Mol Genet 2007; 16: 1367-1380.
62. De Jonge R, Hooijberg JH, van Zelst BD, Jansen G, Jansen G, van Zantwijk CH et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106: 717-720.
63. Huang L, Tissing WJE, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: Association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 1798-1800.
64. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 1995; 270: 25672-25677.
65. Zhu T, Chen XZ, Steel A, Hediger MA, Smith DE. Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm Res 2000; 17: 526-532.